[
  {
    "text": "<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>\r\n<p><a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",
    "position": 0,
    "name": "Application Received",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "May 2020",
          "fs": "May 2020",
          "change": null
        },
        "Event_Description": {
          "s": "Application received",
          "fs": "Application received",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004iLobUAE"
          },
          "Id": "a0P2P000004iLobUAE",
          "Event_Date__c": "2020-05-26",
          "Event_Description__c": "Application received",
          "Stage__c": "Application Received",
          "Formatted_Date__c": "May 2020",
          "Status_History__c": "a132P000000Bnf2QAC"
        },
        "change": null
      }
    ],
    "dateString": "May 2020",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/\" rel=\"nofollow\">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/\" rel=\"nofollow\">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>\n<p style=\"height: 20px\">&nbsp;</p>\n<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>\n<p style=\"height: 15px\">&nbsp;</p>\n<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>\n<p style=\"height: 20px\">&nbsp;</p>\n<p><a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/\" rel=\"nofollow\">PTAC</a>  and <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//\" rel=\"nofollow\">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",
    "position": 1,
    "name": "Seeking Clinical Advice",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "May 2020",
          "fs": "May 2020",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice required",
          "fs": "Clinical advice required",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004iLocUAE"
          },
          "Id": "a0P2P000004iLocUAE",
          "Event_Date__c": "2020-05-27",
          "Event_Description__c": "Clinical advice required",
          "Stage__c": "Seeking Clinical Advice",
          "Formatted_Date__c": "May 2020",
          "Status_History__c": "a132P000000BnfHQAS"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Jun 2020",
          "fs": "Jun 2020",
          "change": null
        },
        "Event_Description": {
          "s": "Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Friday 21 August 2020",
          "fs": "Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Friday 21 August 2020",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004iLodUAE"
          },
          "Id": "a0P2P000004iLodUAE",
          "Event_Date__c": "2020-06-18",
          "Event_Description__c": "Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Friday 21 August 2020",
          "Stage__c": "Seeking Clinical Advice",
          "Formatted_Date__c": "Jun 2020",
          "Status_History__c": "a132P000000BsYgQAK"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": "<p>The Committee <b>recommended </b>that rituximab for the treatment of membranous nephropathy in the first line in patients at a high risk of progression to end stage renal disease despite conservative measures be funded with a high priority, subject to the following Special Authority Criteria: </p><p style=\"text-align: justify;\"><b style=\"font-size: 9pt;\">Restricted</b></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Indication \u2013 Membranous nephropathy </span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Nephrologist or practitioner on the recommendation of a nephrologist. Approvals valid for 6 weeks.</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">All of the following:</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has biopsy-proven primary/idiopathic membranous nephropathy*; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient remains at high risk</span><sup style=\"font-size: 9pt;\">#</sup><span style=\"font-size: 9pt;\"> of progression to end-stage kidney disease despite more than 3 months of treatment with conservative measures^; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">3.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">The total rituximab dose would not exceed the equivalent of 375mg/m</span><sup style=\"font-size: 9pt;\">2</sup><span style=\"font-size: 9pt;\"> of body surface area per week for a total of 4 weeks.</span></p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\"># high risk of progression to end-stage kidney disease (e.g. defined as &gt;5g/day proteinuria and creatinine clearance</span> (<span style=\"font-size: 9pt;\">estimated glomerular filtration rate (eGFR)) \u2265 40 ml/min/1.73 m</span><sup style=\"font-size: 9pt;\">2</sup><span style=\"font-size: 9pt;\">)</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">^conservative measures include renin-angiotensin system blockade, blood-pressure management, dietary sodium and protein restriction, treatment of dyslipidaemia, and anticoagulation agents.</span></p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Continuation \u2013 Membranous nephropathy</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Nephrologist or practitioner on the recommendation of a nephrologist. Approvals valid for 6 weeks.</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">All of the following:</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient was previously treated with rituximab for membranous nephropathy*; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Treatment with rituximab was previously successful, but the condition has relapsed, and the patient now requires repeat treatment; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">3.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">The total rituximab dose used would not exceed the equivalent of 375 mg/m\u00b2 of body surface area per week for a total of 4 weeks. </span></p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Note: Indications marked with * are unapproved indications.</span></p><p style=\"text-align: justify;\"><br></p><p>The Committee <b>recommended</b> that rituximab for the treatment of membranous nephropathy in patients at a high risk of progression to end stage renal disease despite conservative measures, and/or at a high risk of adverse events from immunosuppressive agents, and/or for patients where alternative treatment regimens have resulted in inadequate response or intolerable side effects, be funded with a high priority, subject to the following Special Authority criteria: </p><p style=\"text-align: justify;\"><b style=\"font-size: 9pt;\">Restricted</b></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Indication \u2013Refractory membranous nephropathy </span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Nephrologist or practitioner on the recommendation of a nephrologist. Approvals valid for 6 weeks.</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">All of the following:</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has biopsy-proven primary/idiopathic membranous nephropathy*; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Treatment with corticosteroids for at least a period of 3 months has been ineffective or associated with evidence of corticosteroid toxicity; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">4.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Treatment with ciclosporin and/or tacrolimus for at least a period of 3 months has been ineffective or discontinued due to intolerable or unacceptable side effects; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">5.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Treatment with cyclophosphamide for at least a period of 3 months has been ineffective or discontinued due to intolerable or unacceptable side effects; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">3.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">The total rituximab dose would not exceed the equivalent of 375mg/m</span><sup style=\"font-size: 9pt;\">2</sup><span style=\"font-size: 9pt;\"> of body surface area per week for a total of 4 weeks.</span></p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Continuation \u2013 Refractory membranous nephropathy</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Nephrologist or practitioner on the recommendation of a nephrologist. Approvals valid for 6 weeks.</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">All of the following:</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient was previously treated with rituximab for membranous nephropathy*; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Treatment with rituximab was previously successful, but the condition has relapsed, and the patient now requires repeat treatment; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">3.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">The total rituximab dose used would not exceed the equivalent of 375 mg/m\u00b2 of body surface area per week for a total of 4 weeks. </span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Note: Indications marked with * are unapproved indications.</span></p><p style=\"text-align: justify;\"><br></p><p>In making the above recommendations, the Committee considered the high health need of this patient group, the suitability of rituximab based on its favourable safety profile compared with current immunosuppressive treatment options, and the evidence supporting a reduction in proteinuria following treatment. </p><p>The Committee considered that, although the evidence for rituximab for the treatment of membranous nephropathy comes primarily from its use as a first-line treatment, nonetheless the higher complete or partial remission rate at 2 years, the lower relapse rate compared with immunosuppressive agents and/or calcineurin inhibitors, and the higher health need of these patients (compared with first-line setting) also supports use of rituximab in a second-line setting following inadequate response or intolerable side effects from immunosuppressive agents.</p>",
          "fs": "<p>The Committee <b>recommended </b>that rituximab for the treatment of membranous nephropathy in the first line in patients at a high risk of progression to end stage renal disease despite conservative measures be funded with a high priority, subject to the following Special Authority Criteria: </p><p style=\"text-align: justify;\"><b style=\"font-size: 9pt;\">Restricted</b></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Indication \u2013 Membranous nephropathy </span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Nephrologist or practitioner on the recommendation of a nephrologist. Approvals valid for 6 weeks.</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">All of the following:</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has biopsy-proven primary/idiopathic membranous nephropathy*; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient remains at high risk</span><sup style=\"font-size: 9pt;\">#</sup><span style=\"font-size: 9pt;\"> of progression to end-stage kidney disease despite more than 3 months of treatment with conservative measures^; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">3.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">The total rituximab dose would not exceed the equivalent of 375mg/m</span><sup style=\"font-size: 9pt;\">2</sup><span style=\"font-size: 9pt;\"> of body surface area per week for a total of 4 weeks.</span></p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\"># high risk of progression to end-stage kidney disease (e.g. defined as &gt;5g/day proteinuria and creatinine clearance</span> (<span style=\"font-size: 9pt;\">estimated glomerular filtration rate (eGFR)) \u2265 40 ml/min/1.73 m</span><sup style=\"font-size: 9pt;\">2</sup><span style=\"font-size: 9pt;\">)</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">^conservative measures include renin-angiotensin system blockade, blood-pressure management, dietary sodium and protein restriction, treatment of dyslipidaemia, and anticoagulation agents.</span></p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Continuation \u2013 Membranous nephropathy</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Nephrologist or practitioner on the recommendation of a nephrologist. Approvals valid for 6 weeks.</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">All of the following:</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient was previously treated with rituximab for membranous nephropathy*; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Treatment with rituximab was previously successful, but the condition has relapsed, and the patient now requires repeat treatment; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">3.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">The total rituximab dose used would not exceed the equivalent of 375 mg/m\u00b2 of body surface area per week for a total of 4 weeks. </span></p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Note: Indications marked with * are unapproved indications.</span></p><p style=\"text-align: justify;\"><br></p><p>The Committee <b>recommended</b> that rituximab for the treatment of membranous nephropathy in patients at a high risk of progression to end stage renal disease despite conservative measures, and/or at a high risk of adverse events from immunosuppressive agents, and/or for patients where alternative treatment regimens have resulted in inadequate response or intolerable side effects, be funded with a high priority, subject to the following Special Authority criteria: </p><p style=\"text-align: justify;\"><b style=\"font-size: 9pt;\">Restricted</b></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Indication \u2013Refractory membranous nephropathy </span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Nephrologist or practitioner on the recommendation of a nephrologist. Approvals valid for 6 weeks.</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">All of the following:</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has biopsy-proven primary/idiopathic membranous nephropathy*; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Treatment with corticosteroids for at least a period of 3 months has been ineffective or associated with evidence of corticosteroid toxicity; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">4.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Treatment with ciclosporin and/or tacrolimus for at least a period of 3 months has been ineffective or discontinued due to intolerable or unacceptable side effects; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">5.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Treatment with cyclophosphamide for at least a period of 3 months has been ineffective or discontinued due to intolerable or unacceptable side effects; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">3.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">The total rituximab dose would not exceed the equivalent of 375mg/m</span><sup style=\"font-size: 9pt;\">2</sup><span style=\"font-size: 9pt;\"> of body surface area per week for a total of 4 weeks.</span></p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Continuation \u2013 Refractory membranous nephropathy</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Nephrologist or practitioner on the recommendation of a nephrologist. Approvals valid for 6 weeks.</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">All of the following:</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient was previously treated with rituximab for membranous nephropathy*; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Treatment with rituximab was previously successful, but the condition has relapsed, and the patient now requires repeat treatment; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">3.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">The total rituximab dose used would not exceed the equivalent of 375 mg/m\u00b2 of body surface area per week for a total of 4 weeks. </span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Note: Indications marked with * are unapproved indications.</span></p><p style=\"text-align: justify;\"><br></p><p>In making the above recommendations, the Committee considered the high health need of this patient group, the suitability of rituximab based on its favourable safety profile compared with current immunosuppressive treatment options, and the evidence supporting a reduction in proteinuria following treatment. </p><p>The Committee considered that, although the evidence for rituximab for the treatment of membranous nephropathy comes primarily from its use as a first-line treatment, nonetheless the higher complete or partial remission rate at 2 years, the lower relapse rate compared with immunosuppressive agents and/or calcineurin inhibitors, and the higher health need of these patients (compared with first-line setting) also supports use of rituximab in a second-line setting following inadequate response or intolerable side effects from immunosuppressive agents.</p>",
          "change": null
        },
        "Published_Discussion": {
          "s": "<p>The Committee noted the clinician application for the use of rituximab in the treatment of membranous nephropathy for adult patients at high risk of developing end stage renal disease (ESRD) despite conservative measures, including those at high risk of adverse events from immunosuppressive therapy or who are intolerant to currently available treatments. </p><p><br></p><p>The Committee considered that the application specified rituximab for use in patients at high risk of adverse events from immunosuppressive treatments, and/or in patients where immunosuppressive treatment regimens have resulted in inadequate response or intolerable side effects. However, the Committee considered that the available evidence supports the use of rituximab in a first-line setting following trial of conservative measures. The Committee considered that the different lines of therapy should therefore be considered separately when making any recommendations.</p><p><br></p><p>The Committee considered that early intervention with rituximab may better control disease progress and reduce onset of disease related complications (including ESRD), as opposed to later use of rituximab as an organ rescue treatment. </p><p><br></p><p>The Committee noted the estimated incidence of membranous nephropathy is between 8-10 cases per million population worldwide. The incidence in New Zealand is unknown but there may be about 16 incident cases per year. The Committee noted that spontaneous recovery occurs in approximately 30% of membranous nephropathy patients. For those who continue to experience symptoms, 40-50% are expected to develop ESRD over a period of 10 years. </p><p><br></p><p>The Committee noted that ESRD may lead to renal failure requiring dialysis (with an associated impact on overall survival) or kidney transplant, which both come at a significant cost to the health system. The Committee also noted that New Zealand has a comparatively low kidney donation rate compared with other countries. Treatments that effectively reduce the need for renal transplantation are therefore particularly relevant to New Zealand. </p><p><br></p><p>The Committee noted that anti-PLA2R circulating antibodies are present in approximately 70% of the membranous nephropathy population, although the diagnosis of membranous nephropathy is based primarily on clinical presentation. The Committee also noted, however, that anti-PLA2R antibodies can be used as a confirmatory diagnostic technique and to assess treatment effectiveness.\u00a0</p><p><br></p><p>The Committee noted that rituximab is a monoclonal antibody that binds specifically to the CD20 surface antigen on B-cells, with this initiating immunologic reactions, induces cell death by apoptosis and depletion of CD20 positive B-cells, which result in decreased subendothelial immune deposits in the glomeruli of the kidney. The Committee noted that dysfunctional B-cells play a role in the pathogenesis of membranous nephropathy, with the resultant B-cell depletion responsible for rituximab\u2019s therapeutic effect.</p><p><br></p><p>The Committee noted that the current treatment paradigm for patients with membranous nephropathy begins with conservative measures including renin-angiotensin system blockade, blood-pressure management, dietary sodium and protein restriction, treatment of dyslipidaemia, and treatment with anticoagulation agents. The Committee noted that response following conservative measures alone occurs in approximately 10% of membranous nephropathy patients. </p><p><br></p><p>The Committee also noted that patients presenting with a moderate to high risk of disease progression, and deteriorating kidney function despite conservative measures, are initiated on immunosuppressant therapies and corticosteroids, with the <a href=\"https://pubmed.ncbi.nlm.nih.gov/9513907/\" target=\"_blank\" style=\"color: windowtext;\">Ponticelli regimen</a> (cyclophosphamide, corticosteroids) considered the most widely used treatment regimen. The Committee considered that the Ponticelli regimen is the appropriate comparator for rituximab in this indication. </p><p><br></p><p>The Committee noted that the currently available immunosuppressant treatments for membranous nephropathy, though effective, are typically associated with potentially severe adverse effects and are therefore poorly tolerated and often discontinued. The Committee noted that cyclophosphamide with corticosteroids, whilst effective in 60-70% of patients, has been linked with an increased risk of cancer, hyperglycaemia, infection, myelosuppression, thromboembolism, haemorrhagic cysts, infertility, and increased hospitalisation. The Committee also noted that whilst treatment with calcineurin inhibitors (ciclosporin or tacrolimus) are effective, these are similarly associated with adverse effects such as hypertension and risk of nephrotoxic effects further reducing kidney function with persistence beyond treatment discontinuation. </p><p><br></p><p>The Committee noted that patients who are not able to tolerate immunosuppressants may be treated with mycophenolate mofetil or adrenocorticotropic hormone (ACTH); however, the Committee considered there to be limited evidence supporting the use of these agents, with use throughout New Zealand unclear. \u00a0</p><p><br></p><p>The Committee noted the evidence from an open-label, randomised controlled trial that compared the use of corticosteroids and cyclophosphamide with supportive therapy (dietary sodium restriction, diuretics and antihypertensive agents excluding renin-angiotensin system blockade) in adults with nephrotic syndrome caused by idiopathic membranous nephropathy (<a href=\"https://pubmed.ncbi.nlm.nih.gov/17494881/\" target=\"_blank\" style=\"color: windowtext;\">Jha et al. J Am Soc Nephrol. 2007;18(6):1899-904</a>). The Committee noted that initial remission (defined as complete when proteinuria declined to \u02c2200 mg/d on at least three occasions, and partial when proteinuria was &gt;200 mg/d but &lt;2 g/d or \u02c250% of baseline) was achieved within one year of randomisation in 29% of the treatment group and 9% of the supportive therapy group, and that relapses occurred in 25% of participants in each treatment group, which were subsequently managed by renin-angiotensin system blockade. The Committee noted that complete remission at ten years was achieved in 25% of the control group and 59% of the treatment group, and that 45% of the control group required dialysis treatment compared with 11% of the treatment group. However, the Committee considered that poor endpoints, and proportion of patients lost to follow-up and/or dropping out of the study, impacted the overall robustness and validity of the trial. \u00a0</p><p><br></p><p>The Committee noted the evidence from a randomised, open-label, multicentre study (n=95) comparing methylprednisolone plus chlorambucil with methylprednisolone plus cyclophosphamide for the treatment of idiopathic membranous nephropathy (<a href=\"https://pubmed.ncbi.nlm.nih.gov/9513907/\" target=\"_blank\" style=\"color: windowtext;\">Ponticelli et al. J Am Soc Nephrol. 1998;9(3):444-50</a>). The Committee noted that either chlorambucil or cyclophosphamide with corticosteroids protected renal function, and that there was no meaningful difference in effect between agents. The Committee considered that this regimen (Ponticelli regimen) is the current standard of care. </p><p><br></p><p>The Committee noted that use of ciclosporin versus cyclophosphamide had been noted by the applicant to vary dependent on patient characteristics and patient-clinician preferences. The Committee noted that cyclophosphamide is predominantly used in New Zealand, Australia, and Europe, while ciclosporin is used predominantly in North America. </p><p><br></p><p>The Committee noted a report by Kidney Disease: Improving Global Outcomes (KDIGO) summarising the evidence available for studies that have investigated cyclophosphamide with corticosteroids in the treatment on membranous nephropathy (<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768298/\" target=\"_blank\" style=\"color: windowtext;\">Rojas-Rivera et al. Clin Kidney J. 2019;12(5):629-38</a>). The Committee noted that induction of complete remission had occurred in approximately 20-25% of patients at 24 months, and that complete remission had occurred in approximately 30-35% of patients in the 40 to 60-month follow-ups. </p><p><br></p><p>The Committee noted a meta-analysis of 36 randomised controlled trials comparing the effectiveness and tolerance of immunosuppressive treatments (cyclophosphamide versus ciclosporin A or tacrolimus) for idiopathic membranous nephropathy (<a href=\"https://pubmed.ncbi.nlm.nih.gov/28898290/\" target=\"_blank\" style=\"color: windowtext;\">Ren et al. PLoS One. 2017;2(9):e0184398</a>). The Committee noted that overall, immunosuppressant treatment was more effective at managing membranous nephropathy than non-immunosuppressive treatment, with no meaningful differences in the probability of remission between ciclosporin A and cyclophosphamide, noting drug withdrawal was more likely with cyclophosphamide than with ciclosporin A or tacrolimus. The Committee noted that the evidence for treatment with calcineurin inhibitors beyond 12-18 months is lacking, however this treatment remains common in the USA. The Committee noted that the relapse rate with immunosuppressants is approximately 25%.</p><p><br></p><p>The Committee noted the results from an open label, randomised, multi-centre, non-inferiority, phase III trial (MENTOR trial, n=130), in which patients with membranous nephropathy with proteinuria of 5 g/day despite at least 3 months of renin-angiotensin system blockade, and a glomerular filtration rate (eGFR) of at least 40 mL/min/1.73 m2 were treated for 12 months with either rituximab (1000 mg IV on days 1 and 15, repeated at 6 months in the event of partial remission) or dose-adjusted ciclosporin, where the primary outcome was a composite of complete or partial remission of proteinuria at 24 months (<a href=\"https://pubmed.ncbi.nlm.nih.gov/31269364/\" target=\"_blank\" style=\"color: windowtext;\">Fervenza et al. N Eng J Med. 2019;381(1):36-46</a>). The Committee considered proteinuria to be a well-established and useful surrogate marker for ESRD.\u00a0</p><p><br></p><p>The Committee noted that 39/65 patients (60%) in the rituximab group and 34/65 (52%) in the ciclosporin A group achieved complete or partial remission at 12 months (P&lt;0.004), and that 23 rituximab patients (35%) and no ciclosporin A patients achieved complete remission at 24 months. The Committee noted that 26 patients (40%) of the rituximab group and 52 patients (80%) of the ciclosporin group experienced treatment failure by 24 months (hazard ratio (HR) 0.34, 95% confidence interval (CI) 0.21 to 0.54). The Committee noted that the rate of treatment failure for the rituximab group was approximately 5%, compared to 62% in the ciclosporin group during the 12-month observation period (HR 0.05, 95% CI 0.01 to 0.23). The Committee noted that serious adverse events were less common with rituximab, occurring in 11/65 patients (17%) versus 20/65 (31%) in the ciclosporin A group (P=0.06), and that kidney function was better preserved in the rituximab group. The Committee noted that the decline in anti-PILA2R antibodies was faster and of greater magnitude in rituximab group, which reflected improvement in clinical presentation</p><p>The Committee noted however that the trial did not include the use of cyclophosphamide or corticosteroids, which would be relevant for comparison with the New Zealand membranous nephropathy patient population, and that baseline eGFR differed between the two treatment groups. The Committee considered the definitions of partial and complete response to be unclear, and that response rates for patients treated with immunosuppressants plateau after 4 years and considered that a 2-year follow-up study may be too short to glean clinically meaningful longer-term results. The Committee also noted that there is no evidence for the use of rituximab following immunosuppressive therapy.</p><p><br></p><p>The Committee noted a retrospective, observational cohort study (n=103) in which the safety of rituximab was compared with corticosteroids and cyclophosphamide in the treatment of membranous nephropathy (<a href=\"https://pubmed.ncbi.nlm.nih.gov/28487395/\" target=\"_blank\" style=\"color: windowtext;\">van den Brand et al. J Am Soc Nephrol. 2017;28(9):2729-37</a>). The Committee noted that there were fewer adverse events in the rituximab treatment group, in both serious (11 vs. 46, adjusted HR 0.32, 95% CI 0.15-0.68) and non-serious (52 vs. 127, adjusted HR 0.23, 95% CI 0.13-0.41) adverse events. The Committee noted that rates of complete remission and the composite renal end point did not differ between groups. </p><p><br></p><p>The Committee noted that there are currently two clinical trials underway investigating the use of rituximab compared with other treatments for membranous nephropathy: </p><p>The RI-CYCLO study of rituximab versus corticosteroids and cyclophosphamide in the treatment of idiopathic membranous nephropathy (ClinicalTrials.gov identifier: NCT03018535)</p><p>The STARMEN study, a European multicentre and open-label controlled randomised trial to evaluate the efficacy of sequential treatment with tacrolimus-rituximab versus corticosteroids plus cyclophosphamide in patients with primary membranous Nephropathy (<a href=\"https://pubmed.ncbi.nlm.nih.gov/26413273/\" target=\"_blank\" style=\"color: windowtext;\">Rojas-Rivera et al. Clin Kidney J. 2015;8(5):503-10</a>, ClinicalTrials.gov Identifier: NCT01955187). </p><p><br></p><p>The Committee considered that the results from these trials may provide more robustness to the evidence for the use of rituximab in the treatment of membranous nephropathy. </p><p><br></p><p>The Committee considered that funding rituximab for the treatment of membranous nephropathy may increase DHB associated costs secondary to the requirement for multiple hospital based infusions, but considered that there would also likely be cost offsets associated with a delay in the requirement for management of complications due to nephrotic syndrome, and renal replacement therapy as a result of rituximab treatment. The Committee considered that duration of response with rituximab after 2 years is unknown and it is unclear if patients would require re-treatment after this time.\u00a0</p>",
          "fs": "<p>The Committee noted the clinician application for the use of rituximab in the treatment of membranous nephropathy for adult patients at high risk of developing end stage renal disease (ESRD) despite conservative measures, including those at high risk of adverse events from immunosuppressive therapy or who are intolerant to currently available treatments. </p><p><br></p><p>The Committee considered that the application specified rituximab for use in patients at high risk of adverse events from immunosuppressive treatments, and/or in patients where immunosuppressive treatment regimens have resulted in inadequate response or intolerable side effects. However, the Committee considered that the available evidence supports the use of rituximab in a first-line setting following trial of conservative measures. The Committee considered that the different lines of therapy should therefore be considered separately when making any recommendations.</p><p><br></p><p>The Committee considered that early intervention with rituximab may better control disease progress and reduce onset of disease related complications (including ESRD), as opposed to later use of rituximab as an organ rescue treatment. </p><p><br></p><p>The Committee noted the estimated incidence of membranous nephropathy is between 8-10 cases per million population worldwide. The incidence in New Zealand is unknown but there may be about 16 incident cases per year. The Committee noted that spontaneous recovery occurs in approximately 30% of membranous nephropathy patients. For those who continue to experience symptoms, 40-50% are expected to develop ESRD over a period of 10 years. </p><p><br></p><p>The Committee noted that ESRD may lead to renal failure requiring dialysis (with an associated impact on overall survival) or kidney transplant, which both come at a significant cost to the health system. The Committee also noted that New Zealand has a comparatively low kidney donation rate compared with other countries. Treatments that effectively reduce the need for renal transplantation are therefore particularly relevant to New Zealand. </p><p><br></p><p>The Committee noted that anti-PLA2R circulating antibodies are present in approximately 70% of the membranous nephropathy population, although the diagnosis of membranous nephropathy is based primarily on clinical presentation. The Committee also noted, however, that anti-PLA2R antibodies can be used as a confirmatory diagnostic technique and to assess treatment effectiveness.\u00a0</p><p><br></p><p>The Committee noted that rituximab is a monoclonal antibody that binds specifically to the CD20 surface antigen on B-cells, with this initiating immunologic reactions, induces cell death by apoptosis and depletion of CD20 positive B-cells, which result in decreased subendothelial immune deposits in the glomeruli of the kidney. The Committee noted that dysfunctional B-cells play a role in the pathogenesis of membranous nephropathy, with the resultant B-cell depletion responsible for rituximab\u2019s therapeutic effect.</p><p><br></p><p>The Committee noted that the current treatment paradigm for patients with membranous nephropathy begins with conservative measures including renin-angiotensin system blockade, blood-pressure management, dietary sodium and protein restriction, treatment of dyslipidaemia, and treatment with anticoagulation agents. The Committee noted that response following conservative measures alone occurs in approximately 10% of membranous nephropathy patients. </p><p><br></p><p>The Committee also noted that patients presenting with a moderate to high risk of disease progression, and deteriorating kidney function despite conservative measures, are initiated on immunosuppressant therapies and corticosteroids, with the <a href=\"https://pubmed.ncbi.nlm.nih.gov/9513907/\" target=\"_blank\" style=\"color: windowtext;\">Ponticelli regimen</a> (cyclophosphamide, corticosteroids) considered the most widely used treatment regimen. The Committee considered that the Ponticelli regimen is the appropriate comparator for rituximab in this indication. </p><p><br></p><p>The Committee noted that the currently available immunosuppressant treatments for membranous nephropathy, though effective, are typically associated with potentially severe adverse effects and are therefore poorly tolerated and often discontinued. The Committee noted that cyclophosphamide with corticosteroids, whilst effective in 60-70% of patients, has been linked with an increased risk of cancer, hyperglycaemia, infection, myelosuppression, thromboembolism, haemorrhagic cysts, infertility, and increased hospitalisation. The Committee also noted that whilst treatment with calcineurin inhibitors (ciclosporin or tacrolimus) are effective, these are similarly associated with adverse effects such as hypertension and risk of nephrotoxic effects further reducing kidney function with persistence beyond treatment discontinuation. </p><p><br></p><p>The Committee noted that patients who are not able to tolerate immunosuppressants may be treated with mycophenolate mofetil or adrenocorticotropic hormone (ACTH); however, the Committee considered there to be limited evidence supporting the use of these agents, with use throughout New Zealand unclear. \u00a0</p><p><br></p><p>The Committee noted the evidence from an open-label, randomised controlled trial that compared the use of corticosteroids and cyclophosphamide with supportive therapy (dietary sodium restriction, diuretics and antihypertensive agents excluding renin-angiotensin system blockade) in adults with nephrotic syndrome caused by idiopathic membranous nephropathy (<a href=\"https://pubmed.ncbi.nlm.nih.gov/17494881/\" target=\"_blank\" style=\"color: windowtext;\">Jha et al. J Am Soc Nephrol. 2007;18(6):1899-904</a>). The Committee noted that initial remission (defined as complete when proteinuria declined to \u02c2200 mg/d on at least three occasions, and partial when proteinuria was &gt;200 mg/d but &lt;2 g/d or \u02c250% of baseline) was achieved within one year of randomisation in 29% of the treatment group and 9% of the supportive therapy group, and that relapses occurred in 25% of participants in each treatment group, which were subsequently managed by renin-angiotensin system blockade. The Committee noted that complete remission at ten years was achieved in 25% of the control group and 59% of the treatment group, and that 45% of the control group required dialysis treatment compared with 11% of the treatment group. However, the Committee considered that poor endpoints, and proportion of patients lost to follow-up and/or dropping out of the study, impacted the overall robustness and validity of the trial. \u00a0</p><p><br></p><p>The Committee noted the evidence from a randomised, open-label, multicentre study (n=95) comparing methylprednisolone plus chlorambucil with methylprednisolone plus cyclophosphamide for the treatment of idiopathic membranous nephropathy (<a href=\"https://pubmed.ncbi.nlm.nih.gov/9513907/\" target=\"_blank\" style=\"color: windowtext;\">Ponticelli et al. J Am Soc Nephrol. 1998;9(3):444-50</a>). The Committee noted that either chlorambucil or cyclophosphamide with corticosteroids protected renal function, and that there was no meaningful difference in effect between agents. The Committee considered that this regimen (Ponticelli regimen) is the current standard of care. </p><p><br></p><p>The Committee noted that use of ciclosporin versus cyclophosphamide had been noted by the applicant to vary dependent on patient characteristics and patient-clinician preferences. The Committee noted that cyclophosphamide is predominantly used in New Zealand, Australia, and Europe, while ciclosporin is used predominantly in North America. </p><p><br></p><p>The Committee noted a report by Kidney Disease: Improving Global Outcomes (KDIGO) summarising the evidence available for studies that have investigated cyclophosphamide with corticosteroids in the treatment on membranous nephropathy (<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768298/\" target=\"_blank\" style=\"color: windowtext;\">Rojas-Rivera et al. Clin Kidney J. 2019;12(5):629-38</a>). The Committee noted that induction of complete remission had occurred in approximately 20-25% of patients at 24 months, and that complete remission had occurred in approximately 30-35% of patients in the 40 to 60-month follow-ups. </p><p><br></p><p>The Committee noted a meta-analysis of 36 randomised controlled trials comparing the effectiveness and tolerance of immunosuppressive treatments (cyclophosphamide versus ciclosporin A or tacrolimus) for idiopathic membranous nephropathy (<a href=\"https://pubmed.ncbi.nlm.nih.gov/28898290/\" target=\"_blank\" style=\"color: windowtext;\">Ren et al. PLoS One. 2017;2(9):e0184398</a>). The Committee noted that overall, immunosuppressant treatment was more effective at managing membranous nephropathy than non-immunosuppressive treatment, with no meaningful differences in the probability of remission between ciclosporin A and cyclophosphamide, noting drug withdrawal was more likely with cyclophosphamide than with ciclosporin A or tacrolimus. The Committee noted that the evidence for treatment with calcineurin inhibitors beyond 12-18 months is lacking, however this treatment remains common in the USA. The Committee noted that the relapse rate with immunosuppressants is approximately 25%.</p><p><br></p><p>The Committee noted the results from an open label, randomised, multi-centre, non-inferiority, phase III trial (MENTOR trial, n=130), in which patients with membranous nephropathy with proteinuria of 5 g/day despite at least 3 months of renin-angiotensin system blockade, and a glomerular filtration rate (eGFR) of at least 40 mL/min/1.73 m2 were treated for 12 months with either rituximab (1000 mg IV on days 1 and 15, repeated at 6 months in the event of partial remission) or dose-adjusted ciclosporin, where the primary outcome was a composite of complete or partial remission of proteinuria at 24 months (<a href=\"https://pubmed.ncbi.nlm.nih.gov/31269364/\" target=\"_blank\" style=\"color: windowtext;\">Fervenza et al. N Eng J Med. 2019;381(1):36-46</a>). The Committee considered proteinuria to be a well-established and useful surrogate marker for ESRD.\u00a0</p><p><br></p><p>The Committee noted that 39/65 patients (60%) in the rituximab group and 34/65 (52%) in the ciclosporin A group achieved complete or partial remission at 12 months (P&lt;0.004), and that 23 rituximab patients (35%) and no ciclosporin A patients achieved complete remission at 24 months. The Committee noted that 26 patients (40%) of the rituximab group and 52 patients (80%) of the ciclosporin group experienced treatment failure by 24 months (hazard ratio (HR) 0.34, 95% confidence interval (CI) 0.21 to 0.54). The Committee noted that the rate of treatment failure for the rituximab group was approximately 5%, compared to 62% in the ciclosporin group during the 12-month observation period (HR 0.05, 95% CI 0.01 to 0.23). The Committee noted that serious adverse events were less common with rituximab, occurring in 11/65 patients (17%) versus 20/65 (31%) in the ciclosporin A group (P=0.06), and that kidney function was better preserved in the rituximab group. The Committee noted that the decline in anti-PILA2R antibodies was faster and of greater magnitude in rituximab group, which reflected improvement in clinical presentation</p><p>The Committee noted however that the trial did not include the use of cyclophosphamide or corticosteroids, which would be relevant for comparison with the New Zealand membranous nephropathy patient population, and that baseline eGFR differed between the two treatment groups. The Committee considered the definitions of partial and complete response to be unclear, and that response rates for patients treated with immunosuppressants plateau after 4 years and considered that a 2-year follow-up study may be too short to glean clinically meaningful longer-term results. The Committee also noted that there is no evidence for the use of rituximab following immunosuppressive therapy.</p><p><br></p><p>The Committee noted a retrospective, observational cohort study (n=103) in which the safety of rituximab was compared with corticosteroids and cyclophosphamide in the treatment of membranous nephropathy (<a href=\"https://pubmed.ncbi.nlm.nih.gov/28487395/\" target=\"_blank\" style=\"color: windowtext;\">van den Brand et al. J Am Soc Nephrol. 2017;28(9):2729-37</a>). The Committee noted that there were fewer adverse events in the rituximab treatment group, in both serious (11 vs. 46, adjusted HR 0.32, 95% CI 0.15-0.68) and non-serious (52 vs. 127, adjusted HR 0.23, 95% CI 0.13-0.41) adverse events. The Committee noted that rates of complete remission and the composite renal end point did not differ between groups. </p><p><br></p><p>The Committee noted that there are currently two clinical trials underway investigating the use of rituximab compared with other treatments for membranous nephropathy: </p><p>The RI-CYCLO study of rituximab versus corticosteroids and cyclophosphamide in the treatment of idiopathic membranous nephropathy (ClinicalTrials.gov identifier: NCT03018535)</p><p>The STARMEN study, a European multicentre and open-label controlled randomised trial to evaluate the efficacy of sequential treatment with tacrolimus-rituximab versus corticosteroids plus cyclophosphamide in patients with primary membranous Nephropathy (<a href=\"https://pubmed.ncbi.nlm.nih.gov/26413273/\" target=\"_blank\" style=\"color: windowtext;\">Rojas-Rivera et al. Clin Kidney J. 2015;8(5):503-10</a>, ClinicalTrials.gov Identifier: NCT01955187). </p><p><br></p><p>The Committee considered that the results from these trials may provide more robustness to the evidence for the use of rituximab in the treatment of membranous nephropathy. </p><p><br></p><p>The Committee considered that funding rituximab for the treatment of membranous nephropathy may increase DHB associated costs secondary to the requirement for multiple hospital based infusions, but considered that there would also likely be cost offsets associated with a delay in the requirement for management of complications due to nephrotic syndrome, and renal replacement therapy as a result of rituximab treatment. The Committee considered that duration of response with rituximab after 2 years is unknown and it is unclear if patients would require re-treatment after this time.\u00a0</p>",
          "change": null
        },
        "Published_Application": {
          "s": "<p>The Committee reviewed the application for rituximab for the treatment of membranous nephropathy. </p><p>The Committee took into account, where applicable, PHARMAC\u2019s relevant decision-making framework when considering this agenda item.\u00a0</p>",
          "fs": "<p>The Committee reviewed the application for rituximab for the treatment of membranous nephropathy. </p><p>The Committee took into account, where applicable, PHARMAC\u2019s relevant decision-making framework when considering this agenda item.\u00a0</p>",
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": "High",
          "fs": "High",
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Nov 2020",
          "fs": "Nov 2020",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 21 August 2020.",
          "fs": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 21 August 2020.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004iLoeUAE"
          },
          "Id": "a0P2P000004iLoeUAE",
          "Event_Date__c": "2020-11-09",
          "Event_Description__c": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 21 August 2020.",
          "Stage__c": "Seeking Clinical Advice",
          "Outcome__c": "High",
          "Formatted_Date__c": "Nov 2020",
          "Published_Recommendation__c": "<p>The Committee <b>recommended </b>that rituximab for the treatment of membranous nephropathy in the first line in patients at a high risk of progression to end stage renal disease despite conservative measures be funded with a high priority, subject to the following Special Authority Criteria: </p><p style=\"text-align: justify;\"><b style=\"font-size: 9pt;\">Restricted</b></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Indication \u2013 Membranous nephropathy </span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Nephrologist or practitioner on the recommendation of a nephrologist. Approvals valid for 6 weeks.</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">All of the following:</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has biopsy-proven primary/idiopathic membranous nephropathy*; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient remains at high risk</span><sup style=\"font-size: 9pt;\">#</sup><span style=\"font-size: 9pt;\"> of progression to end-stage kidney disease despite more than 3 months of treatment with conservative measures^; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">3.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">The total rituximab dose would not exceed the equivalent of 375mg/m</span><sup style=\"font-size: 9pt;\">2</sup><span style=\"font-size: 9pt;\"> of body surface area per week for a total of 4 weeks.</span></p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\"># high risk of progression to end-stage kidney disease (e.g. defined as &gt;5g/day proteinuria and creatinine clearance</span> (<span style=\"font-size: 9pt;\">estimated glomerular filtration rate (eGFR)) \u2265 40 ml/min/1.73 m</span><sup style=\"font-size: 9pt;\">2</sup><span style=\"font-size: 9pt;\">)</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">^conservative measures include renin-angiotensin system blockade, blood-pressure management, dietary sodium and protein restriction, treatment of dyslipidaemia, and anticoagulation agents.</span></p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Continuation \u2013 Membranous nephropathy</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Nephrologist or practitioner on the recommendation of a nephrologist. Approvals valid for 6 weeks.</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">All of the following:</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient was previously treated with rituximab for membranous nephropathy*; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Treatment with rituximab was previously successful, but the condition has relapsed, and the patient now requires repeat treatment; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">3.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">The total rituximab dose used would not exceed the equivalent of 375 mg/m\u00b2 of body surface area per week for a total of 4 weeks. </span></p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Note: Indications marked with * are unapproved indications.</span></p><p style=\"text-align: justify;\"><br></p><p>The Committee <b>recommended</b> that rituximab for the treatment of membranous nephropathy in patients at a high risk of progression to end stage renal disease despite conservative measures, and/or at a high risk of adverse events from immunosuppressive agents, and/or for patients where alternative treatment regimens have resulted in inadequate response or intolerable side effects, be funded with a high priority, subject to the following Special Authority criteria: </p><p style=\"text-align: justify;\"><b style=\"font-size: 9pt;\">Restricted</b></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Indication \u2013Refractory membranous nephropathy </span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Nephrologist or practitioner on the recommendation of a nephrologist. Approvals valid for 6 weeks.</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">All of the following:</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has biopsy-proven primary/idiopathic membranous nephropathy*; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Treatment with corticosteroids for at least a period of 3 months has been ineffective or associated with evidence of corticosteroid toxicity; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">4.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Treatment with ciclosporin and/or tacrolimus for at least a period of 3 months has been ineffective or discontinued due to intolerable or unacceptable side effects; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">5.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Treatment with cyclophosphamide for at least a period of 3 months has been ineffective or discontinued due to intolerable or unacceptable side effects; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">3.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">The total rituximab dose would not exceed the equivalent of 375mg/m</span><sup style=\"font-size: 9pt;\">2</sup><span style=\"font-size: 9pt;\"> of body surface area per week for a total of 4 weeks.</span></p><p style=\"text-align: justify;\"><br></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Continuation \u2013 Refractory membranous nephropathy</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">Nephrologist or practitioner on the recommendation of a nephrologist. Approvals valid for 6 weeks.</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">All of the following:</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient was previously treated with rituximab for membranous nephropathy*; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Treatment with rituximab was previously successful, but the condition has relapsed, and the patient now requires repeat treatment; and</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">3.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">The total rituximab dose used would not exceed the equivalent of 375 mg/m\u00b2 of body surface area per week for a total of 4 weeks. </span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span></p><p style=\"text-align: justify;\"><span style=\"font-size: 9pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Note: Indications marked with * are unapproved indications.</span></p><p style=\"text-align: justify;\"><br></p><p>In making the above recommendations, the Committee considered the high health need of this patient group, the suitability of rituximab based on its favourable safety profile compared with current immunosuppressive treatment options, and the evidence supporting a reduction in proteinuria following treatment. </p><p>The Committee considered that, although the evidence for rituximab for the treatment of membranous nephropathy comes primarily from its use as a first-line treatment, nonetheless the higher complete or partial remission rate at 2 years, the lower relapse rate compared with immunosuppressive agents and/or calcineurin inhibitors, and the higher health need of these patients (compared with first-line setting) also supports use of rituximab in a second-line setting following inadequate response or intolerable side effects from immunosuppressive agents.</p>",
          "Published_Application__c": "<p>The Committee reviewed the application for rituximab for the treatment of membranous nephropathy. </p><p>The Committee took into account, where applicable, PHARMAC\u2019s relevant decision-making framework when considering this agenda item.\u00a0</p>",
          "Published_Discussion__c": "<p>The Committee noted the clinician application for the use of rituximab in the treatment of membranous nephropathy for adult patients at high risk of developing end stage renal disease (ESRD) despite conservative measures, including those at high risk of adverse events from immunosuppressive therapy or who are intolerant to currently available treatments. </p><p><br></p><p>The Committee considered that the application specified rituximab for use in patients at high risk of adverse events from immunosuppressive treatments, and/or in patients where immunosuppressive treatment regimens have resulted in inadequate response or intolerable side effects. However, the Committee considered that the available evidence supports the use of rituximab in a first-line setting following trial of conservative measures. The Committee considered that the different lines of therapy should therefore be considered separately when making any recommendations.</p><p><br></p><p>The Committee considered that early intervention with rituximab may better control disease progress and reduce onset of disease related complications (including ESRD), as opposed to later use of rituximab as an organ rescue treatment. </p><p><br></p><p>The Committee noted the estimated incidence of membranous nephropathy is between 8-10 cases per million population worldwide. The incidence in New Zealand is unknown but there may be about 16 incident cases per year. The Committee noted that spontaneous recovery occurs in approximately 30% of membranous nephropathy patients. For those who continue to experience symptoms, 40-50% are expected to develop ESRD over a period of 10 years. </p><p><br></p><p>The Committee noted that ESRD may lead to renal failure requiring dialysis (with an associated impact on overall survival) or kidney transplant, which both come at a significant cost to the health system. The Committee also noted that New Zealand has a comparatively low kidney donation rate compared with other countries. Treatments that effectively reduce the need for renal transplantation are therefore particularly relevant to New Zealand. </p><p><br></p><p>The Committee noted that anti-PLA2R circulating antibodies are present in approximately 70% of the membranous nephropathy population, although the diagnosis of membranous nephropathy is based primarily on clinical presentation. The Committee also noted, however, that anti-PLA2R antibodies can be used as a confirmatory diagnostic technique and to assess treatment effectiveness.\u00a0</p><p><br></p><p>The Committee noted that rituximab is a monoclonal antibody that binds specifically to the CD20 surface antigen on B-cells, with this initiating immunologic reactions, induces cell death by apoptosis and depletion of CD20 positive B-cells, which result in decreased subendothelial immune deposits in the glomeruli of the kidney. The Committee noted that dysfunctional B-cells play a role in the pathogenesis of membranous nephropathy, with the resultant B-cell depletion responsible for rituximab\u2019s therapeutic effect.</p><p><br></p><p>The Committee noted that the current treatment paradigm for patients with membranous nephropathy begins with conservative measures including renin-angiotensin system blockade, blood-pressure management, dietary sodium and protein restriction, treatment of dyslipidaemia, and treatment with anticoagulation agents. The Committee noted that response following conservative measures alone occurs in approximately 10% of membranous nephropathy patients. </p><p><br></p><p>The Committee also noted that patients presenting with a moderate to high risk of disease progression, and deteriorating kidney function despite conservative measures, are initiated on immunosuppressant therapies and corticosteroids, with the <a href=\"https://pubmed.ncbi.nlm.nih.gov/9513907/\" target=\"_blank\" style=\"color: windowtext;\">Ponticelli regimen</a> (cyclophosphamide, corticosteroids) considered the most widely used treatment regimen. The Committee considered that the Ponticelli regimen is the appropriate comparator for rituximab in this indication. </p><p><br></p><p>The Committee noted that the currently available immunosuppressant treatments for membranous nephropathy, though effective, are typically associated with potentially severe adverse effects and are therefore poorly tolerated and often discontinued. The Committee noted that cyclophosphamide with corticosteroids, whilst effective in 60-70% of patients, has been linked with an increased risk of cancer, hyperglycaemia, infection, myelosuppression, thromboembolism, haemorrhagic cysts, infertility, and increased hospitalisation. The Committee also noted that whilst treatment with calcineurin inhibitors (ciclosporin or tacrolimus) are effective, these are similarly associated with adverse effects such as hypertension and risk of nephrotoxic effects further reducing kidney function with persistence beyond treatment discontinuation. </p><p><br></p><p>The Committee noted that patients who are not able to tolerate immunosuppressants may be treated with mycophenolate mofetil or adrenocorticotropic hormone (ACTH); however, the Committee considered there to be limited evidence supporting the use of these agents, with use throughout New Zealand unclear. \u00a0</p><p><br></p><p>The Committee noted the evidence from an open-label, randomised controlled trial that compared the use of corticosteroids and cyclophosphamide with supportive therapy (dietary sodium restriction, diuretics and antihypertensive agents excluding renin-angiotensin system blockade) in adults with nephrotic syndrome caused by idiopathic membranous nephropathy (<a href=\"https://pubmed.ncbi.nlm.nih.gov/17494881/\" target=\"_blank\" style=\"color: windowtext;\">Jha et al. J Am Soc Nephrol. 2007;18(6):1899-904</a>). The Committee noted that initial remission (defined as complete when proteinuria declined to \u02c2200 mg/d on at least three occasions, and partial when proteinuria was &gt;200 mg/d but &lt;2 g/d or \u02c250% of baseline) was achieved within one year of randomisation in 29% of the treatment group and 9% of the supportive therapy group, and that relapses occurred in 25% of participants in each treatment group, which were subsequently managed by renin-angiotensin system blockade. The Committee noted that complete remission at ten years was achieved in 25% of the control group and 59% of the treatment group, and that 45% of the control group required dialysis treatment compared with 11% of the treatment group. However, the Committee considered that poor endpoints, and proportion of patients lost to follow-up and/or dropping out of the study, impacted the overall robustness and validity of the trial. \u00a0</p><p><br></p><p>The Committee noted the evidence from a randomised, open-label, multicentre study (n=95) comparing methylprednisolone plus chlorambucil with methylprednisolone plus cyclophosphamide for the treatment of idiopathic membranous nephropathy (<a href=\"https://pubmed.ncbi.nlm.nih.gov/9513907/\" target=\"_blank\" style=\"color: windowtext;\">Ponticelli et al. J Am Soc Nephrol. 1998;9(3):444-50</a>). The Committee noted that either chlorambucil or cyclophosphamide with corticosteroids protected renal function, and that there was no meaningful difference in effect between agents. The Committee considered that this regimen (Ponticelli regimen) is the current standard of care. </p><p><br></p><p>The Committee noted that use of ciclosporin versus cyclophosphamide had been noted by the applicant to vary dependent on patient characteristics and patient-clinician preferences. The Committee noted that cyclophosphamide is predominantly used in New Zealand, Australia, and Europe, while ciclosporin is used predominantly in North America. </p><p><br></p><p>The Committee noted a report by Kidney Disease: Improving Global Outcomes (KDIGO) summarising the evidence available for studies that have investigated cyclophosphamide with corticosteroids in the treatment on membranous nephropathy (<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768298/\" target=\"_blank\" style=\"color: windowtext;\">Rojas-Rivera et al. Clin Kidney J. 2019;12(5):629-38</a>). The Committee noted that induction of complete remission had occurred in approximately 20-25% of patients at 24 months, and that complete remission had occurred in approximately 30-35% of patients in the 40 to 60-month follow-ups. </p><p><br></p><p>The Committee noted a meta-analysis of 36 randomised controlled trials comparing the effectiveness and tolerance of immunosuppressive treatments (cyclophosphamide versus ciclosporin A or tacrolimus) for idiopathic membranous nephropathy (<a href=\"https://pubmed.ncbi.nlm.nih.gov/28898290/\" target=\"_blank\" style=\"color: windowtext;\">Ren et al. PLoS One. 2017;2(9):e0184398</a>). The Committee noted that overall, immunosuppressant treatment was more effective at managing membranous nephropathy than non-immunosuppressive treatment, with no meaningful differences in the probability of remission between ciclosporin A and cyclophosphamide, noting drug withdrawal was more likely with cyclophosphamide than with ciclosporin A or tacrolimus. The Committee noted that the evidence for treatment with calcineurin inhibitors beyond 12-18 months is lacking, however this treatment remains common in the USA. The Committee noted that the relapse rate with immunosuppressants is approximately 25%.</p><p><br></p><p>The Committee noted the results from an open label, randomised, multi-centre, non-inferiority, phase III trial (MENTOR trial, n=130), in which patients with membranous nephropathy with proteinuria of 5 g/day despite at least 3 months of renin-angiotensin system blockade, and a glomerular filtration rate (eGFR) of at least 40 mL/min/1.73 m2 were treated for 12 months with either rituximab (1000 mg IV on days 1 and 15, repeated at 6 months in the event of partial remission) or dose-adjusted ciclosporin, where the primary outcome was a composite of complete or partial remission of proteinuria at 24 months (<a href=\"https://pubmed.ncbi.nlm.nih.gov/31269364/\" target=\"_blank\" style=\"color: windowtext;\">Fervenza et al. N Eng J Med. 2019;381(1):36-46</a>). The Committee considered proteinuria to be a well-established and useful surrogate marker for ESRD.\u00a0</p><p><br></p><p>The Committee noted that 39/65 patients (60%) in the rituximab group and 34/65 (52%) in the ciclosporin A group achieved complete or partial remission at 12 months (P&lt;0.004), and that 23 rituximab patients (35%) and no ciclosporin A patients achieved complete remission at 24 months. The Committee noted that 26 patients (40%) of the rituximab group and 52 patients (80%) of the ciclosporin group experienced treatment failure by 24 months (hazard ratio (HR) 0.34, 95% confidence interval (CI) 0.21 to 0.54). The Committee noted that the rate of treatment failure for the rituximab group was approximately 5%, compared to 62% in the ciclosporin group during the 12-month observation period (HR 0.05, 95% CI 0.01 to 0.23). The Committee noted that serious adverse events were less common with rituximab, occurring in 11/65 patients (17%) versus 20/65 (31%) in the ciclosporin A group (P=0.06), and that kidney function was better preserved in the rituximab group. The Committee noted that the decline in anti-PILA2R antibodies was faster and of greater magnitude in rituximab group, which reflected improvement in clinical presentation</p><p>The Committee noted however that the trial did not include the use of cyclophosphamide or corticosteroids, which would be relevant for comparison with the New Zealand membranous nephropathy patient population, and that baseline eGFR differed between the two treatment groups. The Committee considered the definitions of partial and complete response to be unclear, and that response rates for patients treated with immunosuppressants plateau after 4 years and considered that a 2-year follow-up study may be too short to glean clinically meaningful longer-term results. The Committee also noted that there is no evidence for the use of rituximab following immunosuppressive therapy.</p><p><br></p><p>The Committee noted a retrospective, observational cohort study (n=103) in which the safety of rituximab was compared with corticosteroids and cyclophosphamide in the treatment of membranous nephropathy (<a href=\"https://pubmed.ncbi.nlm.nih.gov/28487395/\" target=\"_blank\" style=\"color: windowtext;\">van den Brand et al. J Am Soc Nephrol. 2017;28(9):2729-37</a>). The Committee noted that there were fewer adverse events in the rituximab treatment group, in both serious (11 vs. 46, adjusted HR 0.32, 95% CI 0.15-0.68) and non-serious (52 vs. 127, adjusted HR 0.23, 95% CI 0.13-0.41) adverse events. The Committee noted that rates of complete remission and the composite renal end point did not differ between groups. </p><p><br></p><p>The Committee noted that there are currently two clinical trials underway investigating the use of rituximab compared with other treatments for membranous nephropathy: </p><p>The RI-CYCLO study of rituximab versus corticosteroids and cyclophosphamide in the treatment of idiopathic membranous nephropathy (ClinicalTrials.gov identifier: NCT03018535)</p><p>The STARMEN study, a European multicentre and open-label controlled randomised trial to evaluate the efficacy of sequential treatment with tacrolimus-rituximab versus corticosteroids plus cyclophosphamide in patients with primary membranous Nephropathy (<a href=\"https://pubmed.ncbi.nlm.nih.gov/26413273/\" target=\"_blank\" style=\"color: windowtext;\">Rojas-Rivera et al. Clin Kidney J. 2015;8(5):503-10</a>, ClinicalTrials.gov Identifier: NCT01955187). </p><p><br></p><p>The Committee considered that the results from these trials may provide more robustness to the evidence for the use of rituximab in the treatment of membranous nephropathy. </p><p><br></p><p>The Committee considered that funding rituximab for the treatment of membranous nephropathy may increase DHB associated costs secondary to the requirement for multiple hospital based infusions, but considered that there would also likely be cost offsets associated with a delay in the requirement for management of complications due to nephrotic syndrome, and renal replacement therapy as a result of rituximab treatment. The Committee considered that duration of response with rituximab after 2 years is unknown and it is unclear if patients would require re-treatment after this time.\u00a0</p>",
          "Status_History__c": "a132P000000CKkfQAG"
        },
        "change": null
      }
    ],
    "dateString": "May 2020",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/\" rel=\"nofollow\">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>\r\n<p>&nbsp;</p>\r\n<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>\r\n<ul>\r\n<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>\r\n<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>\r\n<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>\r\n</ul>\r\n<p>&nbsp;</p>\r\n<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",
    "position": 2,
    "name": "Under Assessment",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Nov 2020",
          "fs": "Nov 2020",
          "change": null
        },
        "Event_Description": {
          "s": "Working to compare options",
          "fs": "Working to compare options",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004iLpJUAU"
          },
          "Id": "a0P2P000004iLpJUAU",
          "Event_Date__c": "2020-11-24",
          "Event_Description__c": "Working to compare options",
          "Stage__c": "Under Assessment",
          "Formatted_Date__c": "Nov 2020",
          "Status_History__c": "a132P000000CNRWQA4"
        },
        "change": null
      }
    ],
    "dateString": "Nov 2020",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac\u2019s decision-making process.</p>\r\n<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>\r\n<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>\r\n<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",
    "position": 3,
    "name": "Options Compared",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Dec 2020",
          "fs": "Dec 2020",
          "change": null
        },
        "Event_Description": {
          "s": "The relative ranking of the pharmaceutical application has been completed.",
          "fs": "The relative ranking of the pharmaceutical application has been completed.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004iLpLUAU"
          },
          "Id": "a0P2P000004iLpLUAU",
          "Event_Date__c": "2020-12-16",
          "Event_Description__c": "The relative ranking of the pharmaceutical application has been completed.",
          "Stage__c": "Options Compared",
          "Formatted_Date__c": "Dec 2020",
          "Status_History__c": "a132P000000CSGoQAO"
        },
        "change": null
      }
    ],
    "dateString": "Dec 2020",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>\r\n<p><a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",
    "position": 4,
    "name": "Under Consultation",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Dec 2020",
          "fs": "Dec 2020",
          "change": null
        },
        "Event_Description": {
          "s": "Public consultation for this application is active.",
          "fs": "Public consultation for this application is active.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004iLpKUAU"
          },
          "Id": "a0P2P000004iLpKUAU",
          "Event_Date__c": "2020-12-04",
          "Event_Description__c": "Public consultation for this application is active.",
          "Stage__c": "Under Consultation",
          "Formatted_Date__c": "Dec 2020",
          "Status_History__c": "a132P000000CPeVQAW"
        },
        "change": null
      },
      {
        "Summary": {
          "s": "https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/consultation-2020-12-04-rituximab/",
          "fs": "https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/consultation-2020-12-04-rituximab/",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Jan 2021",
          "fs": "Jan 2021",
          "change": null
        },
        "Event_Description": {
          "s": "Public consultation for this application is active.",
          "fs": "Public consultation for this application is active.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004iLpMUAU"
          },
          "Id": "a0P2P000004iLpMUAU",
          "Event_Date__c": "2021-01-22",
          "Event_Description__c": "Public consultation for this application is active.",
          "Stage__c": "Under Consultation",
          "Summary__c": "https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/consultation-2020-12-04-rituximab/",
          "Formatted_Date__c": "Jan 2021",
          "Status_History__c": "a132P000000CX4TQAW"
        },
        "change": null
      }
    ],
    "dateString": "Dec 2020",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",
    "position": 5,
    "name": "Reviewing Consultation Feedback",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": "https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/consultation-2020-12-04-rituximab/",
          "fs": "https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/consultation-2020-12-04-rituximab/",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Jan 2021",
          "fs": "Jan 2021",
          "change": null
        },
        "Event_Description": {
          "s": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "fs": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004iLpNUAU"
          },
          "Id": "a0P2P000004iLpNUAU",
          "Event_Date__c": "2021-01-22",
          "Event_Description__c": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "Stage__c": "Reviewing Consultation Feedback",
          "Summary__c": "https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/consultation-2020-12-04-rituximab/",
          "Formatted_Date__c": "Jan 2021",
          "Status_History__c": "a132P000000CX4YQAW"
        },
        "change": null
      }
    ],
    "dateString": "Jan 2021",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>\r\n<p>We consider and assess all funding decisions using the&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc\" rel=\"nofollow\">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>\r\n<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>\r\n<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>\r\n<p>&nbsp;</p>",
    "position": 6,
    "name": "Decision",
    "last": true,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": "<p>https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2021-02-12-rituximab/</p>",
          "fs": "<p>https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2021-02-12-rituximab/</p>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Feb 2021",
          "fs": "Feb 2021",
          "change": null
        },
        "Event_Description": {
          "s": "The funding application has been approved.",
          "fs": "The funding application has been approved.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004iLpOUAU"
          },
          "Id": "a0P2P000004iLpOUAU",
          "Event_Date__c": "2021-02-12",
          "Event_Description__c": "The funding application has been approved.",
          "Stage__c": "Decision",
          "Links__c": "<p>https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2021-02-12-rituximab/</p>",
          "Formatted_Date__c": "Feb 2021",
          "Status_History__c": "a132P000000CaYrQAK"
        },
        "change": null
      }
    ],
    "dateString": "Feb 2021",
    "collapsed": false,
    "checked": true
  }
]